97 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
17 May 24
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
5:00pm
materials have been posted to the Investor Relations section of Athira’s website (http://investors.athira.com/): the Zoom meeting information for the final
DEFA14A
ATHA
Athira Pharma Inc
9 Apr 24
Additional proxy soliciting materials
8:34am
Materials
Soliciting Material under §240.14a-12
ATHIRA PHARMA, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy … materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
PRE 14A
ATHA
Athira Pharma Inc
28 Mar 24
Preliminary proxy
8:47am
Additional Materials
☐ Soliciting Material under §240.14a-12
ATHIRA PHARMA, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s … with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
PRELIMINARY PROXY
8-K
EX-10.1
duvwy h1e75fh3l
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-10.1
1s87 3n8hllmvt5wx
8 Jan 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
7:11am
8-K
EX-10.3
lsk5zi6qr33cexrs03
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
DEFA14A
xvlnq9ri54o6lle8b6o
5 Apr 23
Additional proxy soliciting materials
7:18am
DEFA14A
et5q bcuo
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
0k0o917 7w
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
h8o8l
16 May 22
Additional proxy materials by non-management
2:04pm
DFAN14A
EX-99.1
79cg5dh6ptgkp8qha
16 May 22
Additional proxy materials by non-management
2:04pm